Engineering Soluble Recombinant BCMA for Ide-Cel Labeling

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy targets B-cell maturation antigen (BCMA) for multiple myeloma (MM).
• Idecabtagene vicleucel (ide-cel) shows promise in relapsed/refractory MM (R/RMM).
• Monitoring CAR-T cell expansion is crucial for predicting patient outcomes.

Purpose of the Study:

• To develop novel, cost-effective fluorescent and soluble BCMA reagents for CAR-T cell monitoring.
• To overcome limitations of existing expensive monitoring tools.

Main Methods:

• Engineered recombinant BCMA extracellular domain fused to fluorescent proteins (GFP, mCherry).
• Incorporated interferon-α2 signal peptide to enable secretion.
• Tested specificity of reagents for anti-BCMA CAR-T cells.

Main Results:

• A signal peptide was essential for BCMA-fusion protein trafficking and secretion.
• Developed soluble BCMA-GFP and BCMA-mCherry fusion proteins.
• These reagents specifically labeled anti-BCMA CAR-T cells.

Conclusions:

• Established a cost-effective method for generating soluble BCMA probes.
• Provided accessible tools for monitoring CAR-T cells in translational research.
• Facilitates improved patient outcome prediction in MM therapy.